l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
Identifieur interne : 001557 ( Main/Exploration ); précédent : 001556; suivant : 001558l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
Auteurs : L K Prashanth [Canada] ; Susan Fox ; Wassilios G. MeissnerSource :
- International review of neurobiology [ 0074-7742 ] ; 2011.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- epidemiology : Dyskinesias.
- genetics : Dyskinesias.
- history : Dyskinesias.
- therapy : Dyskinesias.
- Animals, History, 20th Century, Humans, Risk Factors.
Abstract
Levodopa-induced dyskinesia (LID) has been recognized since the introduction of levodopa for the management of Parkinson's disease (PD) and continues to be one of the most clinically challenging factors in long-term management of patients with PD. Most patients develop LID within 10 years of PD onset and the cause has been attributed to various factors including disease demographics, pharmacological, and possibly genetic causes. The clinical pattern of LID varies and shows intra and inter-patient variability and has been classified based upon phenomenology and relation to timing of levodopa. The potential armamentarium to address and manage LID has significantly increased in the last decade. This chapter addresses the current understanding of various clinical aspects and available therapeutics for LID.
DOI: 10.1016/B978-0-12-381328-2.00002-X
PubMed: 21907082
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C67
- to stream PubMed, to step Curation: 000C67
- to stream PubMed, to step Checkpoint: 000C67
- to stream Ncbi, to step Merge: 000F56
- to stream Ncbi, to step Curation: 000F56
- to stream Ncbi, to step Checkpoint: 000F56
- to stream Main, to step Merge: 001619
- to stream Main, to step Curation: 001557
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.</title><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name><affiliation wicri:level="4"><nlm:affiliation>Morton & Gloria Shulman Movement Disorders Center, and Division of Neurology, University of Toronto, Toronto Western Hospital, 399, Bathurst Street, Toronto, Ontario, Canada M5V 2S8.</nlm:affiliation><country>Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center, and Division of Neurology, University of Toronto, Toronto Western Hospital, 399, Bathurst Street, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21907082</idno><idno type="pmid">21907082</idno><idno type="doi">10.1016/B978-0-12-381328-2.00002-X</idno><idno type="wicri:Area/PubMed/Corpus">000C67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C67</idno><idno type="wicri:Area/PubMed/Curation">000C67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C67</idno><idno type="wicri:Area/PubMed/Checkpoint">000C67</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C67</idno><idno type="wicri:Area/Ncbi/Merge">000F56</idno><idno type="wicri:Area/Ncbi/Curation">000F56</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F56</idno><idno type="wicri:doubleKey">0074-7742:2011:Prashanth L:l:dopa:induced</idno><idno type="wicri:Area/Main/Merge">001619</idno><idno type="wicri:Area/Main/Curation">001557</idno><idno type="wicri:Area/Main/Exploration">001557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.</title><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name><affiliation wicri:level="4"><nlm:affiliation>Morton & Gloria Shulman Movement Disorders Center, and Division of Neurology, University of Toronto, Toronto Western Hospital, 399, Bathurst Street, Toronto, Ontario, Canada M5V 2S8.</nlm:affiliation><country>Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center, and Division of Neurology, University of Toronto, Toronto Western Hospital, 399, Bathurst Street, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name></author></analytic><series><title level="j">International review of neurobiology</title><idno type="ISSN">0074-7742</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Dyskinesias (epidemiology)</term><term>Dyskinesias (genetics)</term><term>Dyskinesias (history)</term><term>Dyskinesias (therapy)</term><term>History, 20th Century</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="history" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>History, 20th Century</term><term>Humans</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa-induced dyskinesia (LID) has been recognized since the introduction of levodopa for the management of Parkinson's disease (PD) and continues to be one of the most clinically challenging factors in long-term management of patients with PD. Most patients develop LID within 10 years of PD onset and the cause has been attributed to various factors including disease demographics, pharmacological, and possibly genetic causes. The clinical pattern of LID varies and shows intra and inter-patient variability and has been classified based upon phenomenology and relation to timing of levodopa. The potential armamentarium to address and manage LID has significantly increased in the last decade. This chapter addresses the current understanding of various clinical aspects and available therapeutics for LID.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21907082
|texte= l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21907082" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |